Publication Name	World Journal of Cardiology
Manuscript ID	95056
Country	India

Received	2024-03-31 08:54
Peer-Review Started	2024-03-31 08:54
To Make the First Decision
Return for Revision	2024-08-12 05:58
Revised	2024-08-25 07:53
Second Decision	2024-09-06 03:06
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-06 09:07
Articles in Press	2024-09-06 09:07
Publication Fee Transferred	2024-09-23 09:57
Edit the Manuscript by Language Editor	2024-10-01 02:49
Typeset the Manuscript	2024-10-14 01:29
Publish the Manuscript Online	2024-10-17 14:39

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi and Vici
Manuscript Source	Unsolicited Manuscript
All Author List	Monika Bhandari, Akshyaya Pradhan, Pravesh Vishwakarma, Abhishek Singh and Rishi Sethi
ORCID	Author(s) ORCID Number Monika Bhandari http://orcid.org/0000-0002-4699-8633 Akshyaya Pradhan http://orcid.org/0000-0002-2360-7580 Pravesh Vishwakarma http://orcid.org/0000-0003-4454-2189 Abhishek Singh http://orcid.org/0000-0003-0494-4220 Rishi Sethi http://orcid.org/0000-0002-6745-6235
Funding Agency and Grant Number
Corresponding Author	Akshyaya Pradhan, FACC, FCCP, FESC, MBBS, MD, Professor, Department of Cardiology, King Georg’s Medical University, Shahmina Road, Chowk, Lucknow 226003, Uttar Pradesh, India. akshyaya33@gmail.com
Key Words	Heart failure with preserved ejection fraction; Gliflozins; Diuresis; Natriuresis; N terminal-pro brain natriuretic peptide; Heart failure hospitalization
Core Tip	Heart failure (HF) is a chronic disease associated with high morbidity and mortality rates. Sodium glucose cotransporter-2 inhibitors (SGLT-2i) represent a new class of pharmacological agents approved for diabetes mellitus (DM) who also demonstrated significant improvement in renal and cardiovascular (CV) outcomes along with good glycemic control. Multiple mechanisms have been proposed for the pleiotropic effects beyond glycemic control. Subsequently, two landmark studies of SGLT-2i in patients with HF, EMPEROR-Reduced (empagliflozin outcome trial in patients with chronic HF and a reduced ejection fraction) and dapagliflozin and prevention of adverse outcomes in HF (DAPA-HF), demonstrated significant improvement in HF hospitalization and CV mortality, irrespective of the presence of DM. These impressive results pitchforked these drugs as class I indications in patients with HF with reduced ejection fraction across major guidelines. Thereafter, empagliflozin outcome trial in patients with chronic HF with preserved ejection fraction (EMPEROR-Preserved) and dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction HF (DELIVER trials) in succession proved that SGLT-2i also benefit patients with HF with preserved ejection fraction with or without DM. Emerging positive data for SGLT-2i in AHF and post-myocardial infarction scenarios have bolstered the pivotal role of these agents in the full diapason of HF. In a short span of time, these classes of drugs have captivated the entire scenario of HF.
Publish Date	2024-10-17 14:39
Citation	<p>Bhandari M, Pradhan A, Vishwakarma P, Singh A, Sethi R. Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi and Vici. <i>World J Cardiol</i> 2024; 16(10): 550-563</p>
URL	https://www.wjgnet.com/1949-8462/full/v16/i10/550.htm
DOI	https://dx.doi.org/10.4330/wjc.v16.i10.550

Full Article (PDF)	WJC-16-550-with-cover.pdf
Manuscript File	95056_Auto_Edited_033745.docx
Answering Reviewers	95056-answering-reviewers.pdf
Audio Core Tip	95056-audio.mp3
Conflict-of-Interest Disclosure Form	95056-conflict-of-interest-statement.pdf
Copyright License Agreement	95056-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	95056-non-native-speakers.pdf
Peer-review Report	95056-peer-reviews.pdf
Scientific Misconduct Check	95056-scientific-misconduct-check.png
Scientific Editor Work List	95056-scientific-editor-work-list.pdf
CrossCheck Report	95056-crosscheck-report.png
CrossCheck Report	95056-crosscheck-report.pdf